BlackRock has cleared its Q2 earnings hurdle, and the data now shifts from pre-print positioning to post-print reality — with the bull case intact but one notable crack in analyst confidence.
The most telling single move this week came from Morgan Stanley. Mike Cyprys, who raised his target to $1,430 as recently as late June, trimmed it back to $1,383 on July 14 while keeping his Overweight rating. The cut is modest in absolute terms but carries signal value: Cyprys was among the most constructive voices into the print, and pulling the target even slightly suggests the quarter was solid without being the upside surprise the most bullish scenarios required. The broader analyst picture remains decisively positive, however. Barclays, Evercore ISI, and Keefe Bruyette & Woods all raised targets last week ahead of results, and the consensus mean sits at $1,260 — roughly 23% above the current price of $1,025. That gap is wide enough to keep the overall Street posture firmly in the bull camp even after Morgan Stanley's adjustment.
Options positioning has also shifted since the pre-earnings note published July 12. The put/call ratio, which had fallen below 0.95 ahead of results, has edged back up to 0.99 — still slightly below its 20-day average of 1.03 but no longer at the near-extreme call skew seen pre-print. That move is consistent with traders unwinding short-dated calls after the event, rather than a fresh wave of defensive hedging. The z-score of -0.49 confirms positioning is only modestly call-leaning relative to recent history — not a strong directional read either way.
Short interest and borrow conditions remain entirely unbothered by the earnings catalyst. At 1.35% of free float, short interest has drifted up roughly 3% on the week — from around 2.03 million to 2.09 million shares — but the absolute level is trivial. Borrow availability is effectively unconstrained, with the lending pool showing no signs of tightness. Cost to borrow has collapsed to 0.19%, down from a brief spike above 0.92% in early July. That earlier spike has fully unwound and the CTB is now at its lowest level of the past six weeks. There is no squeeze dynamic here, and no evidence that short sellers are pressing the stock after results.
The factor scorecard adds texture to the bull case. BlackRock ranks in the 94th percentile on forward EPS growth trajectory — the clearest quantitative signal that analysts are still materially upgrading their earnings forecasts for the out-years. The 81st percentile EPS surprise rank reflects a consistent history of beating estimates, and the dividend score at the 96th percentile flags BlackRock as a standout income compounder within its sector. The bear case centres on cost creep: G&A expenses are running up 13%+ and operating margin estimates have been revised down to the low 44% range, a step back from prior expectations. That is the tension the Morgan Stanley target trim implicitly acknowledges — growth is there, but the margin expansion story is taking longer to play out.
Among peers, IVZ and APAM both outpaced BLK on the week, gaining 4.9% and 6.5% respectively, while BX added 3%. BlackRock's 1.6% weekly gain looks modest by comparison, though it is worth noting the stock started the week at a higher base. The post-earnings drift toward $1,025 — effectively flat on the month — means the Q2 print has neither re-rated the stock sharply higher nor triggered a meaningful unwind.
What to watch next is whether the Morgan Stanley target reduction proves a lone data point or the start of a modest target-compression cycle among the more bullish houses — the distance between the current price and the consensus mean leaves room for several cuts before the Street turns cautious.
See the live data behind this article on ORTEX.
Open BLK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
